Pieris Pharmaceuticals (NASDAQ:PIRS) issued its earnings results on Monday. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.18, Fidelity Earnings reports. Pieris Pharmaceuticals had a negative return on equity of 114.25% and a negative net margin of 147.19%. The business had revenue of $15.13 million during the quarter, compared to analysts’ expectations of $6.28 million.
Shares of NASDAQ PIRS traded down $0.12 during trading on Tuesday, reaching $3.83. The company had a trading volume of 10,696 shares, compared to its average volume of 497,449. The company’s fifty day moving average price is $3.53 and its 200-day moving average price is $4.20. Pieris Pharmaceuticals has a 12 month low of $2.39 and a 12 month high of $6.04. The stock has a market cap of $192.63 million, a P/E ratio of -7.90 and a beta of 1.26.
PIRS has been the subject of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Pieris Pharmaceuticals in a report on Monday. Robert W. Baird cut Pieris Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 target price for the company. in a report on Tuesday, July 30th. ValuEngine cut Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, September 27th. Zacks Investment Research raised Pieris Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a report on Saturday. Finally, William Blair reaffirmed a “buy” rating on shares of Pieris Pharmaceuticals in a report on Monday. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $5.42.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Featured Article: Are all No-Load Funds Equal?
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.